Eledon Pharmaceuticals (ELDN) Net Cash Flow (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Net Cash Flow data on file, last reported at -$16.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 38.19% year-over-year to -$16.7 million; the trailing twelve-month figure through Mar 2026 stood at -$2.3 million (down 182.51% YoY), and the FY2025 full-year result was $2.3 million, down 85.83% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$16.7 million, down from $19.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $20.4 million in Q2 2024 and bottomed at -$37.3 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$6.2 million (2022), against an average of -$4.8 million.
• The widest annual swing landed in 2024, when Net Cash Flow jumped 1360.11%; it then plunged 1255.61% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$9.5 million in 2022, then surged by 109.97% to $945000.0 in 2023, then surged by 1360.11% to $13.8 million in 2024, then soared by 38.71% to $19.1 million in 2025, then plunged by 187.03% to -$16.7 million in 2026.
• The last three Net Cash Flow figures came in at -$16.7 million (Q1 2026), $19.1 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.

Peer Comparison